Žana Bumbulienė

Prof. Dr. Žana Bumbulienė

Medical Faculty, Institute of Clinical Medicine, Clinic of Obstetrics and Gynaecology, Vilnius University, Vilnius, Vilniaus Miestas, Lithuania
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2017 in Contemporary Clinical Trials
Verified
Journal Article
Open access
CSChristian Seitz
Christian Seitz
ŽBŽana Bumbulienė
Žana Bumbulienė
ACAna Rosa Costa
Ana Rosa Costa
OHOskari Heikinheimo
Oskari Heikinheimo
AHAndrea Heweker
Andrea Heweker
KGKristina Gemzell-Danielsson
Kristina Gemzell-Danielsson
Uterine fibroids (UFs) may be treated with progesterone receptor modulators (PRMs), which have been shown to reduce heavy menstrual bleeding and the size of UFs. To date, one PRM (ulipristal acetate) has received regulatory approval for the treatment of UFs; therapy comprises intermittent treatment courses of up to 3months each, followed by a break to allow two menstruations to occur. We report the design of ASTEROID (Assess Safety and efficacy of vilaprisan in patients with uTERine fibrOIDs) 2, a phase 2 study examining the efficacy and safety of a novel PRM, vilaprisan, in women with UFs. In this randomized multi-arm study, vilaprisan (2mg daily) will be administered in different regimens: continuous treatment for 12 or 24weeks, or two 12-week treatment periods separated by a break to allow one menstruation to occur. Efficacy and safety will be compared with that of ulipristal acetate (5mg daily) and placebo. Patients randomized to receive placebo for 12weeks will also be given active treatment for 12weeks. The primary measure of efficacy will be amenorrhoea rate; secondary measures include time to normalized menstrual bleeding and percentage change in UF volume. Endometrial changes will be monitored throughout the study. The placebo- and active comparator-controlled trial ASTEROID 2 is the first study to evaluate systematically the efficacy and safety of different treatment regimens of PRMs in women with UFs. The findings of this study will direct the planning of future clinical trials of vilaprisan.

1 August 2014 in Archives of Gynecology and Obstetrics
Verified
Journal Article
Closed access
PDF file
IPI. Pilypienė
I. Pilypienė
NDN. Drazdienė
N. Drazdienė
IDI. Dumalakienė
I. Dumalakienė
NVN. Vezbergienė
N. Vezbergienė
DBD. Bartkevičienė
D. Bartkevičienė
ŽBŽana Bumbulienė
Žana Bumbulienė

27 November 2018 in Gynecological Endocrinology
Verified
Journal Article
Closed access
ŽBŽana Bumbulienė
Žana Bumbulienė
DSDiana Sragyte
Diana Sragyte
JKJelena Klimasenko
Jelena Klimasenko
EBElzbieta Bumbul-Mazurek
Elzbieta Bumbul-Mazurek
Objective: To evaluate ultrasonographic measurements of internal genitalia in girls suffering from abnormal uterine bleeding (AUB) and to compare the appearances with those of healthy girls. DESIGN Prospective case – control study. Methods: One hundred and five not sexually active adolescent girls were enrolled – 67 patients were suffering from AUB and there were 38 healthy peers. The groups did not differ in chronological age, or in postmenarcheal age. All girls underwent assessment of their history, clinical data and transabdominal pelvic ultrasound to evaluate their uterus and ovaries. In order to avoid the impact of endometrium cycle fluctuations, the uterine volume was calculated including and excluding its thickness. Results: The uterine volume among the girls suffering from AUB was significantly larger than in the control group. The mean uterine volume including endometrium in the study and control groups was 63.2 ± 24.8 and 47.8 ± 17.5 cm3, respectively (p=.001), and excluding the endometrium was 34.7 ± 13.1 and 29.1 ± 13.8 cm3 (p=.043). We did not find any significant difference in ovarian volume between the groups. Conclusions: The girls in the AUB group have significantly larger uterine volume than healthy girls. This finding does not depend on endometrial thickness.

8 May 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
MKMariola Krzyścin
Mariola Krzyścin
ESElżbieta Sowińska-Przepiera
Elżbieta Sowińska-Przepiera
KGKarolina Gruca-Stryjak
Karolina Gruca-Stryjak
ESEwelina Soszka-Przepiera
Ewelina Soszka-Przepiera
ISIgor Syrenicz
Igor Syrenicz
ASAnhelli Syrenicz
Anhelli Syrenicz
Introduction: Metabolic syndrome (MetS), characterized by visceral obesity, glucose abnormalities, hypertension and dyslipidemia, poses a significant risk of diabetes and cardiovascular disease. Turner syndrome (TS), resulting from X chromosome abnormalities, carries health complications. Despite growing evidence of an increased risk of MetS in women with TS, its prevalence and risk factors remain under investigation. These considerations are further complicated by the varying timing and dosages of treatment with growth hormone and sex hormones. Methods: We conducted a cross-sectional study comparing 44 individuals with TS with 52 age-matched control subjects. Growth hormone treatment in the study group was administered for varying lengths of time, depending on clinical response. We collected anthropometric, metabolic, endocrine and body composition data. Statistical analyses included logistic regression. Results: Baseline characteristics, including age, BMI and height, were comparable between the TS and control groups. Hormonally, individuals with TS showed lower levels of testosterone, DHEA-S, and cortisol, as well as elevated FSH. Lipid profiles indicated an atherogenic profile, and the body composition analysis showed increased visceral adipose tissue in those with TS. Other metabolic abnormalities were common in individuals with TS too, including hypertension and impaired fasting glucose levels. The risk of MetS components was assessed in subgroups according to karyotypes: monosomy 45X0 vs. other mosaic karyotypes. Logistic regression analysis showed a significant association between increased visceral adipose tissue in subjects with TS. Those with metabolic complications tended to have less muscle strength compared to those without these complications in both the study and control groups. Conclusions: This study highlights the unique metabolic and cardiovascular risk profile of individuals with TS, characterized by atherogenic lipids, higher levels of visceral adipose tissue and increased metabolic abnormalities. These findings underscore the importance of monitoring metabolic health in individuals with TS, regardless of age, BMI or karyotype, and suggest the potential benefits of lifestyle modification, building more muscle strength, and weight control strategies. Further research is needed to better understand and address the metabolic challenges faced by women with TS.

27 November 2022 in Medicina
Verified
Journal Article
Open access
PDF file
ŽBŽana Bumbulienė
Žana Bumbulienė
DBDiana Buzinskiene
Diana Buzinskiene
GBGreta Banuškevičienė
Greta Banuškevičienė
EŠEvelina Šidlovska
Evelina Šidlovska
EPEglė Preikšaitienė
Eglė Preikšaitienė
AUAlgirdas Utkus
Algirdas Utkus
Background: We report the clinical case of female patient with 46,XY difference of sexual development (DSD) and discuss the challenges in the differential diagnosis between complete gonadal dysgenesis (also called Swyer syndrome) and complete androgen insensitivity syndrome. Case Presentation: The patient’s with primary amenorrhea gynaecological examination and magnetic resonance imaging (MRI) revealed the absence of the uterus and a very short vagina. Two sclerotic structures, similar to ovaries, were recognised bilaterally in the iliac regions. Hormonal assay tests revealed hypergonadotropic hypogonadism and the testosterone level was above normal. The karyotype was 46,XY and a diagnosis of Swyer syndrome was made. At the age of 41, the patient underwent a gynaecological review and after evaluating her tests and medical history, the previous diagnosis was questioned. Therefore, a molecular analysis of sex-determining region Y (SRY) and androgen receptor (AR) genes was made and the results instead led to a definite diagnosis of complete androgen insensitivity syndrome. Conclusions: The presented case illustrates that differentiating between complete gonadal dysgenesis and complete androgen insensitivity can be challenging. A well-established diagnosis is crucial because the risk of malignancy is different in those two syndromes, as well as the timing and importance of gonadectomy.

29 March 2024 in Biomedicines
Verified
Journal Article
Open access
PDF file
ESElżbieta Sowińska-Przepiera
Elżbieta Sowińska-Przepiera
MKMariola Krzyścin
Mariola Krzyścin
ISIgor Syrenicz
Igor Syrenicz
AĆAdrianna Ćwiertnia
Adrianna Ćwiertnia
AZAdrianna Zahorowska
Adrianna Zahorowska
ASAnhelli Syrenicz
Anhelli Syrenicz
The absence of non-invasive methods for assessing bone material and structural changes is a significant diagnostic challenge. Dual-energy X-ray absorptiometry (DXA) bone mineral density (BMD) testing is the gold standard for osteoporosis diagnosis. BMD and the trabecular bone score (TBS) have facilitated targeted osteoporosis prevention and treatment in clinical settings. The findings from this study indicate that BMD modulation in young women is influenced by various hormones, potentially compromising the diagnostic precision of BMD for subclinical bone demineralization. A total of 205 women aged 19 to 37 underwent anthropometric measurements and hormonal tests. BMD was determined using DXA, and TBS values were computed from the lumbar spine L1–L4 segment. The multivariate analysis findings suggest that BMD might not be determined by hormones. The relationship between TBS and TSH was statistically significant in the univariate analysis, which indicates the efficacy of further studies to determine the link between TBS and specific hormones. Analyzing the strength of the correlation between TBS and hormones in the univariate analysis shows which factors are worth considering in further analyses. This makes it possible to create better techniques that will help identify young women who are at a higher risk of developing osteoporosis.